It is estimated that hearing thresholds are elevated in 10-20% of those receiving aminoglycoside antibiotics and as much as 80% in cisplatin-treated patients [3, 6]. However, because of their cost and/or robust effectiveness, these drugs continue to be used while their ototoxic effects often limit drug-dosing paradigms.